ayconsulting.blogspot.com

In sententiam

Occasional commentary and opinion on news and events in medicine and the pharmaceutical and life sciences industries. Saturday, 11 January 2014. Marketed and clinical stage biosimilars for the treatment of autoimmune disease. Following on from a recent post on biosimilars, I've pulled together a list of biosimilar versions of Remicade (infliximab), Humira (adalimumab),Enbrel (entanercept) and Rituxan/MabThera that are either marketed or in clinical development as of January 2014. Thursday, 2 January 2014.

http://ayconsulting.blogspot.com/

OVERVIEW OF ayconsulting.blogspot.com

TRAFFIC RANK

>1,000,000

REVIEWS

0

PAGES IN THIS WEBSITE

9

LINKS TO THIS WEBSITE

CONTACTS

ADDRESSES

SOCIAL LINKS

ONLINE SINCE

WEBSITE DETAILS

SEO

PAGES

SIMILAR SITES

TRAFFIC RANK FOR AYCONSULTING.BLOGSPOT.COM

TODAY'S RATING

>1,000,000

TRAFFIC RANK - AVERAGE PER MONTH

BEST MONTH

September

AVERAGE PER DAY Of THE WEEK

HIGHEST TRAFFIC ON

Monday

TRAFFIC BY CITY

Sign up

CUSTOMER REVIEWS

Average Rating: 3.8 out of 5 with 11 reviews

5 star

4

4 star

5

3 star

0

2 star

0

1 star

2

Hey there! Start your review of ayconsulting.blogspot.com

AVERAGE USER RATING

Write a Review

WEBSITE PREVIEW

LOAD TIME

0.2 seconds

FAVICON PREVIEW

16x16
32x32
64x64
128x128

CONTACTS AT AYCONSULTING.BLOGSPOT.COM

ADD CONTACT

Login

TO VIEW CONTACTS

Remove Contacts

FOR PRIVACY ISSUES

CONTENT

PAGES IN
THIS WEBSITE

9

SSL

EXTERNAL LINKS

0

SITE IP

74.125.228.236

LOAD TIME

0.175 sec

SCORE

6.2

PAGE TITLE

In sententiam | ayconsulting.blogspot.com Reviews

<META> DESCRIPTION

Occasional commentary and opinion on news and events in medicine and the pharmaceutical and life sciences industries. Saturday, 11 January 2014. Marketed and clinical stage biosimilars for the treatment of autoimmune disease. Following on from a recent post on biosimilars, I've pulled together a list of biosimilar versions of Remicade (infliximab), Humira (adalimumab),Enbrel (entanercept) and Rituxan/MabThera that are either marketed or in clinical development as of January 2014. Thursday, 2 January 2014.

<META> KEYWORDS

1 pages

2 update

3 posted by

4 alex yule

5 no comments

6 email this

7 blogthis

8 share to twitter

9 share to facebook

10 share to pinterest

CONTENT

Page content here

KEYWORDS ON PAGE

pages,update,posted by,alex yule,no comments,email this,blogthis,share to twitter,share to facebook,share to pinterest,pseudomonas aeruginosa,paeruginosa,footnote,blood,update 8,microscopic eggs from,trichuris suis,a pig whipworm,coronado press release

SERVER

GSE

CONTENT-TYPE

utf-8

GOOGLE PREVIEW

In sententiam | ayconsulting.blogspot.com Reviews

https://ayconsulting.blogspot.com

Occasional commentary and opinion on news and events in medicine and the pharmaceutical and life sciences industries. Saturday, 11 January 2014. Marketed and clinical stage biosimilars for the treatment of autoimmune disease. Following on from a recent post on biosimilars, I've pulled together a list of biosimilar versions of Remicade (infliximab), Humira (adalimumab),Enbrel (entanercept) and Rituxan/MabThera that are either marketed or in clinical development as of January 2014. Thursday, 2 January 2014.

INTERNAL PAGES

ayconsulting.blogspot.com

1

In sententiam: Justum pretium: an unmet need in cancer treatment

http://www.ayconsulting.blogspot.com/2013/10/justum-pretium-unmet-need-in-cancer.html

Occasional commentary and opinion on news and events in medicine and the pharmaceutical and life sciences industries. Sunday, 27 October 2013. Justum pretium: an unmet need in cancer treatment. 1 Stephen S Hall. The Cost of Living. New York Magazine, October 20th 2013. http:/ nymag.com/news/features/cancer-drugs-2013-10/index1.html#print. 2 Kantarjian, HM et al. 121(22): 4439-42. May 30th, 2013. 3 Kantarjian, HM et al. Cancer Drugs in the United States: Justum Pretium. Subscribe to: Post Comments (Atom).

2

In sententiam: Malaria vaccination: first product approval is on the horizon

http://www.ayconsulting.blogspot.com/2013/10/malaria-vaccination-end-of-beginning.html

Occasional commentary and opinion on news and events in medicine and the pharmaceutical and life sciences industries. Sunday, 13 October 2013. Malaria vaccination: first product approval is on the horizon. GSK intend to submit an application for marketing approval to the European Medicines Agency later this year If approved and accepted by the WHO for inclusion in the package of childhood vaccines, RTS,S (branded as "Mosquirix") could be deployed in Africa by 2015. The vaccine will be sold at cost, p...

3

In sententiam: November 2013

http://www.ayconsulting.blogspot.com/2013_11_01_archive.html

Occasional commentary and opinion on news and events in medicine and the pharmaceutical and life sciences industries. Saturday, 2 November 2013. Pseudomonas aeruginosa vaccination: not anytime soon. Infection poses a significant and potentially lethal threat to patients under intensive care. Efforts to develop a P.aeruginosa. Vaccine go back almost forty years. Despite the application of a host of vaccination strategies (whole bacterial cells, purified membrane and flagella proteins and various antig...

4

In sententiam: Biosimilar antibodies (slowly) rising

http://www.ayconsulting.blogspot.com/2014/01/biosimilar-antibodies-slowly-rising.html

Occasional commentary and opinion on news and events in medicine and the pharmaceutical and life sciences industries. Thursday, 2 January 2014. Biosimilar antibodies (slowly) rising. Biologics are expensive and lower cost biosimilars [1]. Of biosimilar biologic treatment of patients with severe rheumatoid arthritis suggest that, without substantial discount and biosimilar quotas of more than 50%, savings from biosimilar use might be insufficient to treat significant numbers of additional patients without...

5

In sententiam: January 2014

http://www.ayconsulting.blogspot.com/2014_01_01_archive.html

Occasional commentary and opinion on news and events in medicine and the pharmaceutical and life sciences industries. Saturday, 11 January 2014. Marketed and clinical stage biosimilars for the treatment of autoimmune disease. Following on from a recent post on biosimilars, I've pulled together a list of biosimilar versions of Remicade (infliximab), Humira (adalimumab),Enbrel (entanercept) and Rituxan/MabThera that are either marketed or in clinical development as of January 2014. Thursday, 2 January 2014.

UPGRADE TO PREMIUM TO VIEW 4 MORE

TOTAL PAGES IN THIS WEBSITE

9

OTHER SITES

ayconsultant.com

www.ayconsultant.com

3610;ริษัท เอแอนด์วาย คอนซัลแตนท์ จำกัด. 3624;ูนย์รวมอุปกรณ์ดับเพลิงและระบบความปลอดภัย. Email : admin@ayconsultant.com Tel : 086-5066723 Fax : 02-939-9964. 3585;ลับสู่หน้าหลัก. 3626;ินค้าและบริการ. 3649;ผนที่ตั้งบริษัท. 3605;ิดต่อบริษัท.

ayconsultants.com

Accueil

Notre présence en France, au Royaume-Uni et aux Emirats Arabes Unis, nous permet d’intervenir sur des profils à envergure internationale en Afrique, en Europe et au Moyen-Orient. Présents à Aix en Provence, nous apportons une qualité de service à la hauteur des exigences des entreprises situées en région PACA et Rhône Alpes. Londres, UK 44 (0) 208 144 1060. Aix-en-Provence, France 33 (0) 970 44 90 10. Afficher sur le mobile.

ayconsultants.fr

Accueil

Présents à Aix en Provence, nous apportons une qualité de service à la hauteur des exigences des entreprises situées en région PACA et Rhône Alpes. Pour relever les défis d’aujourd’hui et de demain les entreprises doivent pouvoir s’appuyer sur des hommes et des femmes compétents, motivés et impliqués. Notre expérience nous permet de vous aider à mieux recruter pour améliorer les performances de votre entreprise. Aix-en-Provence, France 33 (0) 970 449 010.

ayconsultantsgcc.com

Home

Every Industry depends on its people, their expertise, training, attitude and commitment. Using rigorous recruitment processes we aim to provide you with the best candidates possible for your job. With offices based in Dubai, we are able to bring an excellent level of service to companies based around the GCC. With offices in France and the United Kingdom, our consultants are able to cover any roles you are looking to fill within the EMEA Regions. Dubai - United Arab Emirates 971 (0) 52 624 4312.

ayconsulting.blogspot.com

In sententiam

Occasional commentary and opinion on news and events in medicine and the pharmaceutical and life sciences industries. Saturday, 11 January 2014. Marketed and clinical stage biosimilars for the treatment of autoimmune disease. Following on from a recent post on biosimilars, I've pulled together a list of biosimilar versions of Remicade (infliximab), Humira (adalimumab),Enbrel (entanercept) and Rituxan/MabThera that are either marketed or in clinical development as of January 2014. Thursday, 2 January 2014.

ayconsulting.co.uk

Alexander Yule Consulting

About Alexander Yule Consulting. Working with Alexander Yule Consulting. Occasional commentary and opinion can be found at http:/ ayconsulting.blogspot.co.uk. Articles (before January 2013) are available from the downloadable content page. Business Development Basics. A Guide for Early-Stage Life Science Companies" can be found here:. Feedback, comments and suggestions for an expanded 2nd Edition which I hope to release very early in the new year. Welcome to the AYC website. When do we start? A license o...

ayconsulting.net

IT Consulting San Francisco Information Technology Consulting Firm

Skip to main navigation. Skip to 1st column. Skip to 2nd column. Comprehensive Round-The-Clock IT Support. Proactive. Responsive. Affordable. Effective. Digital Video Security Solutions. We provide installation and service coverage with a high-level of expertise and experience. Network Design and Installation. We deliver scalable network solutions to ensure that you get the right network for your organization. VOIP Business Phone System. Welcome to AY Consulting Inc. We recognize the importance of your t...

aycont.com

AYCONT le da la bienvenida

aycontenidos.com

Ay Contenidos – Productora independiente de Tv, Comunicación y Eventos

Queremos brindar mejores y más eficientes servicios de comunicación a nuestros clientes. Y lo que en un nacimiento fue una productora de contenidos; hoy se convierte en una agencia de publicidad capaz de desarrollar campañas integrales y de alto impacto. Nuestra misión es generar contenidos de calidad y potenciar las ventas de nuestros clientes de manera efectiva. Queremos ser socios estratégicos en la toma de decisiones vinculadas a la comunicación y el posicionamiento en la comunidad. Asesoramos a nues...

aycontextures.com

Aycon Textures

Was successfully added to your cart. Oak brush oiled “Le Mani” by PROFILEGNO. Click here to assign a widget to this area. Click here to assign a widget to this area. Click here to assign a widget to this area. Made possible by the friendly support of. Via Castello, 24 - 36050 Quinto Vicentino (VI). Tel 39 0444 356340 - Fax 39 0444 357628.